Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in patients with
relapsed/refractory hematological malignancies. Research is also extending to other …

Background Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising
treatment option for relapsed or refractory B-cell malignancies and multiple myeloma …

Abstract A registered (PROSPERO-CRD42022346462) systematic review and meta-
analysis was conducted of all-grade infections amongst adult patients receiving CAR-T …

B-cell lymphoma and lymphoproliferative diseases represent a heterogeneous and complex
group of neoplasms that are accompanied by a broad range of immune regulatory disorder …

Chimeric antigen receptor T-cell (CAR T-cell) therapy represents an innovative and
transformative therapy for patients with relapsed and/or refractory (R/R) hematological …

Chimeric antigen receptor (CAR) T cells targeting CD19 represent a promising salvage
immunotherapy for relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL) …

Background Chimeric antigen receptor T cells (CAR-T cells) are increasingly used to treat
haematological malignancies. Strategies for preventing infections in CAR-T-treated patients …

Chimeric antigen receptor T-cell (CAR-T) therapy has shown remarkable effects in treating
various hematological malignancies. However, hematotoxicity, specifically neutropenia …

Current Opinion in Infectious Diseases Log in or Register Subscribe to journalSubscribe Get
new issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …

Managing inflammatory toxicities related to chimeric antigen receptor (CAR) T-cells is an
essential component to facilitate its use as an important therapeutic and allow for its …